GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$26.90
0.35 (1.32%)
▲
5d:
-0.59%
30d:
-8.19%
90d:
-9.09%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GMAB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GMAB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.30
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$39.93
32.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $26.90, which is considered slightly low relative to its 30-day fair value range of $26.58 to $28.28. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.4) compared to its historical average (17.7). Remarkably, the market is currently pricing in an annual earnings decline of 6.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMAB is in a strong downtrend. Immediate support is located at $25.34, while resistance sits at $28.28.
Market Sentiment: GMAB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $37.55 (+39.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GMAB is in a strong downtrend. Immediate support is located at $25.34, while resistance sits at $28.28.
Market Sentiment: GMAB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $37.55 (+39.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$26.58 -
$28.28
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.6% below Wall St target ($37.55)
Trading Range Analysis
30-Day Trading Range
$26.58 -
$28.28
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$25.34
Resistance Level
$28.28
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.42
Wall Street Target
$37.55
(+39.6%)
Revenue Growth (YoY)
25.3%
Earnings Growth (YoY)
-72.8%
Profit Margin
21.1%
Valuation Discount vs History
-6.6% cheaper
PE vs Historical
14.4 vs 17.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.6%
(market-implied from PE analysis)
1-Year Target
$25.12
(-7%)
2-Year Target
$23.47
(-13%)
3-Year Target
$21.92
(-19%)
3-Yr Target (if PE normalizes)
(PE: 14→18)
$26.90
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 70.8%)
$138.77
(+416%)
Base:
(SPY PE: 14.4, Growth: 70.8%)
$90.79
(+238%)
Bear:
(PE: 12.3, Growth: 70.8%)
$77.17
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 20.27 | Current EPS (TTM): $1.31
Bull Case
$41.59
(+55%)
Analyst growth 42.4%, PE expands to 22.3
Base Case
$37.81
(+41%)
Market implied 42.4%, PE stable at 20.3
Bear Case
$18.05
(-33%)
Severe decline -20.0%, PE contracts to 17.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.4 to 17.7
Stabilization Target:
$33.02
(+22.8%)
PE Expansion Potential:
+22.8%
Share & Embed Analysis
Last updated: May 14, 2026 8:16 PM ET
Data refreshes hourly during market hours. Next update: 9:16 PM
Data refreshes hourly during market hours. Next update: 9:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |
